S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer

Microtubule-targeting agents are widely used as active anticancer drugs. However, drug resistance always emerges after their long-term use, especially in the case of paclitaxel, which is the cornerstone of all subtypes of breast cancer treatment. Hence, the development of novel agents to overcome th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Zhenyan, Lin, Songwen, Du, Tingting, Wang, Mingjin, Wang, Weida, You, Shen, Xue, Nina, Liu, Yichen, Ji, Ming, Xu, Heng, Chen, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221130/
https://www.ncbi.nlm.nih.gov/pubmed/37242532
http://dx.doi.org/10.3390/ph16050749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221130/
https://www.ncbi.nlm.nih.gov/pubmed/37242532
http://dx.doi.org/10.3390/ph16050749

Ejemplares similares